Camp4 Therapeutics (CAMP) Preferred Stock Liabilities (2023 - 2024)
Camp4 Therapeutics (CAMP) reported Preferred Stock Liabilities of $162.1 million for Q3 2024, little changed on a YoY basis from $162.1 million in Q4 2023, and little changed sequentially from $162.1 million in Q2 2024.
Camp4 Therapeutics (CAMP) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Camp4 Therapeutics (CAMP) has 2 years of Preferred Stock Liabilities data on file, last reported at $162.1 million in Q3 2024.
- For the quarter ending Q3 2024, Preferred Stock Liabilities changed 0.0% year-over-year to $162.1 million; the trailing twelve-month figure through Sep 2024 stood at $162.1 million (changed 0.0% YoY), and the FY2023 full-year result was $162.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $162.1 million in Q3 2024, from $162.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $162.1 million in Q3 2023 to a low of $162.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Camp4 Therapeutics | 174.35 Mn | 174.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 162.15 Mn |
| Jun 30, 2024 | 162.15 Mn |
| Mar 31, 2024 | 162.15 Mn |
| Dec 31, 2023 | 162.15 Mn |
| Sep 30, 2023 | 162.15 Mn |